SILVER SPRING
Baxfendy cleared as first aldosterone synthase inhibitor for hypertension
- Sponsor
- AstraZeneca $AZN
- Drug
- Baxfendy · baxdrostat
- Indication
- hypertension
FDA approved AstraZeneca's Baxfendy (baxdrostat) as the first aldosterone synthase inhibitor for hypertension in combination with other antihypertensive medications.
What this means
Baxfendy is a blood pressure medication that works by blocking aldosterone production, a hormone that can cause stubborn high blood pressure. The FDA just approved Baxfendy for use alongside other blood pressure drugs in patients who need additional treatment. This gives doctors a new tool for hard-to-control hypertension by targeting a different pathway than existing medications.
Drug Watch — recent news on Baxfendy
- Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial - The Lancet
- Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision (MLYS) - Seeking Alpha
- Baxdrostat Lowers Systolic Blood Pressure in Patients with Uncontrolled or Resistant Hypertension: Phase 3 Trial Results - Vera Health
- Baxfendy (Baxdrostat): Redefining... : Amrita Journal of Medicine - Ovid
- New hypertension drugs show no advantage over older generics - Managed Healthcare Executive
Sponsor Watch — recent news on AstraZeneca
- Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
- AstraZeneca (LSE:AZN) Reported First HER2 Directed Lung Cancer Phase III Success
- AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed
- FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug
- Onco360® Has Been Selected as a National Pharmacy Partner for ETCAMAH™ (camizestrant)